RxDoctor Payments Data

Jennifer Johnson

Family · New York, NYNPI 1346960523

Payments from drug & device makers

$1,629in general payments, 2019–2025

Across 24 payments — averaging $67.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$801
  • Boston Scientific$365
  • Endo Pharmaceuticals Inc.$118
  • Astellas Pharma US Inc$100
  • Daiichi Sankyo Inc.$80
  • Tolmar, Inc.$69
  • plus $95 from 4 others

What the payments were for

  • Travel & lodging$1,05765%
  • Food & beverage$39224%
  • Education$18011%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,629 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$64,968
Medicare patients
200
Services billed
5,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron198$124,727
MyrbetriqMirabegron139$74,495
XyostedTestosterone Enanthate55$34,123
Alfuzosin Hcl ErAlfuzosin Hcl420$7,413
Estradiol65$5,113
Tadalafil43$4,441
Tamsulosin Hcl104$1,655
Finasteride128$1,531
Testosterone Cypionate29$1,030
Solifenacin Succinate14$990
Oxybutynin Chloride ErOxybutynin Chloride16$302
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$276
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$193
Dutasteride12$176
CefuroximeCefuroxime Axetil20$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$74,495139 claims
Antares Pharma, Inc.Xyosted$18$34,12355 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →